Spotlight: Korsuva ™ - The 1st and only FDA-Approved Treatment for CKD-Associated Pruritus

When:  Feb 3, 2022 from 01:00 PM to 02:00 PM (ET)
Associated with  Open Member Community

Korsuva ™ (Difelikefalin):
The 1st and only FDA-approved treatment for moderate to severe CKD-associated pruritus in adult hemodialysis patients
February 3, 2022
1:00 PM ET

The webinar will provide education around CKD-associated pruritus and the impact on the lives of hemodialysis patients.  Also, we will be sharing clinical information on recently approved Korsvuva, the first and only FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease  (CKD-aP) in adults undergoing hemodialysis (HD). 

Learning Objectives 

  • What is chronic kidney disease-associated pruritus?
  • Clinical study results of Korsuva ™ (Difelikefalin)
  • Overview of Korsuva ™ (Difelikefalin) reimbursement